These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 22580613)

  • 1. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.
    Dimberg LY; Anderson CK; Camidge R; Behbakht K; Thorburn A; Ford HL
    Oncogene; 2013 Mar; 32(11):1341-50. PubMed ID: 22580613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
    Cordier SM; Papenfuss K; Walczak H
    Results Probl Cell Differ; 2009; 49():115-43. PubMed ID: 19142621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL of Hope Meeting Resistance in Cancer.
    Deng D; Shah K
    Trends Cancer; 2020 Dec; 6(12):989-1001. PubMed ID: 32718904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of TRAIL--potential and risks of a novel anticancer therapy.
    Koschny R; Walczak H; Ganten TM
    J Mol Med (Berl); 2007 Sep; 85(9):923-35. PubMed ID: 17437073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.
    Singh D; Tewari M; Singh S; Narayan G
    Future Oncol; 2021 Feb; 17(5):581-596. PubMed ID: 33401962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
    Johnstone RW; Frew AJ; Smyth MJ
    Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
    Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
    J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
    Thorburn A; Behbakht K; Ford H
    Drug Resist Updat; 2008; 11(1-2):17-24. PubMed ID: 18374623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.
    Holoch PA; Griffith TS
    Eur J Pharmacol; 2009 Dec; 625(1-3):63-72. PubMed ID: 19836385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL: a sword for killing tumors.
    Wang S
    Curr Med Chem; 2010; 17(29):3309-17. PubMed ID: 20712573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.
    Huang Y; Yang X; Xu T; Kong Q; Zhang Y; Shen Y; Wei Y; Wang G; Chang KJ
    Int J Oncol; 2016 Jul; 49(1):153-63. PubMed ID: 27210546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.
    Gasparini C; Vecchi Brumatti L; Monasta L; Zauli G
    Curr Med Chem; 2013; 20(17):2254-71. PubMed ID: 23458616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined modality therapy with TRAIL or agonistic death receptor antibodies.
    Amm HM; Oliver PG; Lee CH; Li Y; Buchsbaum DJ
    Cancer Biol Ther; 2011 Mar; 11(5):431-49. PubMed ID: 21263219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.
    Menke C; Bin L; Thorburn J; Behbakht K; Ford HL; Thorburn A
    Cancer Res; 2011 Mar; 71(5):1883-92. PubMed ID: 21363923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is TRAIL the holy grail of cancer therapy?
    Newsom-Davis T; Prieske S; Walczak H
    Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL receptor signaling and therapeutics.
    Abdulghani J; El-Deiry WS
    Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Death receptor ligands, in particular TRAIL, to overcome drug resistance.
    de Jong S; Timmer T; Heijenbrok FJ; de Vries EG
    Cancer Metastasis Rev; 2001; 20(1-2):51-6. PubMed ID: 11831647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs.
    Finlay D; Vamos M; González-López M; Ardecky RJ; Ganji SR; Yuan H; Su Y; Cooley TR; Hauser CT; Welsh K; Reed JC; Cosford ND; Vuori K
    Mol Cancer Ther; 2014 Jan; 13(1):5-15. PubMed ID: 24194568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.